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WHAT TORT THEORY TELLS US
ABOUT FEDERAL PREEMPTION:
THE TRAGIC SAGA OF
WYETH V. LEVINE
RICHARD A. EPSTEIN*
I.
INTRODUCTION: THE STATE OF CURRENT
PREEMPTION LAW
Most of the papers in this conference volume grapple with
whether the venerable federal preemption principle will block pri-
vate tort rights of action based on state common law principles.
Federal preemption derives from the Supremacy Clause, which stip-
ulates that federal statutes, and the regulations adopted pursuant to
them, trump any state law.1 Two recent Supreme Court decisions,
Riegel v. Medtronic, Inc.2 and, especially, Wyeth v. Levine,3 now shape
this debate. Taken together, these cases stand for two propositions.
First, the doctrine of express preemption is alive and well in the
Supreme Court; if Congress wants to block state tort actions against
defendants that have complied with federal law, all it has to do is
give the word. Second, while Congress has not spoken to the mat-
ter, recent decisions of the Supreme Court make it exceedingly dif-
ficult for defendants to persuade any court, federal or state, to
preempt ordinary tort law actions under theories of either field or
conflict preemption. 4 Although the final verdict is not in, I am rue-
fully confident that implied preemption in drug duty-to-warn cases
* James Parker Hall Distinguished Service Professor of Law, The University
of Chicago; the Peter and Kirsten Bedford Senior Fellow, The Hoover Institution;
Visiting Professor of Law, New York University. My thanks to the members of the
New York Tort Group for their incisive and persistent criticisms of an earlier
version of this paper, and to Sharon Yecies, University of Chicago Law School, class
of 2011, for her valuable research assistance.
1. U.S. CONST. art. VI, cl. 2 ("This Constitution, and the Laws of the United
States which shall be made in Pursuance thereof; and all Treaties made, or which
shall be made, under the Authority of the United States, shall be the supreme Law
of the Land; and the Judges in every State shall be bound thereby, any Thing in
the Constitution or Laws of any State to the Contrary notwithstanding.").
2. 552 U.S. 312 (2008).
3. 129 S. Ct. 1187 (2009).
4. See, e.g., Bates v. Dow Agrosciences, LLC, 544 U.S. 431, 452-53 (2005); see
also infra text accompanying notes 154-63.
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has, at best, a cloudy future after Wyeth-a point that becomes clear
with an analysis of Colacicco v. Apotex Inc.5
It is no accident that both Riegel and Wyeth arose out of the
interaction between the Food and Drug Administration (FDA) and
state tort law. Riegel held that the Medical Device Amendments of
19766 preempted a state law products liability case brought against
a manufacturer whose device had gone through the FDA's pre-mar-
ket approval process.7 This command precluded the application of
state law.8
In Wyeth, in contrast, the Supreme Court held that a plaintiff
could bring a duty-to-warn case under state law relating to Phener-
gan, an antihistamine marketed continuously since 1955 for the
treatment of nausea.9 Like all drugs made and marketed in the
United States, Phenergan was accompanied by detailed warnings
and instructions approved by the FDA. 10 But unlike the Medical
Devices Act in Riegel, the Food and Drug law contains no explicit
preemption provision for drugs,1" and indeed appears to contain a
provision that limits preemption in cases where there is a "direct
and positive conflict" between the federal statute and any state
law. 12 That provision was read by Judge Sloviter in Colacicco as call-
ing for only a conflict analysis of preemption. 13 But the force of
5. 521 F.3d 253 (3rd Cir. 2008), vacated, 129 S. Ct. 1578, 1578-79 (2009) (re-
manding for further consideration in light of Wyeth, 129 S. Ct. 1187).
6. See Medical Device Amendments of 1976, 21 U.S.C. § 360k (2006) ("[N]o
State or political subdivision of a State may establish or continue in effect with
respect to a device intended for human use any requirement. which is different
from, or in addition to, any requirement applicable under this chapter to the de-
vice, and ... which relates to the safety or effectiveness of the device or to any
other matter included in a requirement applicable to the device under this chap-
ter."). For a perceptive account of the difficulties in construing the forms of state
regulation that are allowed under this provision, see Mark Herrmann, David Booth
Alden & Bradley W. Harrison, The Meaning of the Parallel Requirements Exception
Under Lohr and Riegel, 65 N.Y.U. ANN. SURV. Am. L. 545 (2010).
7. See Riegel, 552 U.S. at 322-23.
8. Id. at 324-25.
9. Wyeth v. Levine, 129 S. Ct. 1187, 1191 (2009).
10. Id. at 1195.
11. Id. at 1193-94, 1196.
12. See Drug Amendments of 1962, Pub. L. No. 87-781, § 202, 76 Stat. 780,
793 (1962) ("Nothing in the amendments made by this Act to the Federal Food,
Drug, and Cosmetic Act shall be construed as invalidating any provision of State
law... unless there is a direct and positive conflict between such amendments and
such provision of State law.").
13. See Colacicco v. Apotex Inc., 521 F.3d 253, 262 n.8 (3d Cir. 2008) ("Of
course, the plain language of this provision states that the Amendments do not
preempt state law in the absence of a conflict. Thus, to the extent that this provi-
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that conclusion is muted when, only one page earlier, she quotes
established Supreme Court case law that rejects any effort to regard
three basic categories of preemption as "rigidly distinct:" "[F]ield
pre-emption may be understood as a species of conflict preemp-
tion: A state law that falls within a pre-empted field conflicts with
Congress' [s] intent (either express or plainly implied) to exclude
state regulation."' 4
If that is correct, the analysis of preemption under the food
and drug laws collapses back into the elaborate body of Supreme
Court rules applicable to implied preemption cases-which all date
back to the watershed case of Rice v. Santa Fe Elevator Corp.,15 which
established a presumption against preemption:
Congress legislated here [on the matter of warehouse receipts]
in a field which the States have traditionally occupied. So we
start with the assumption that the historic police powers of the
States were not to be superseded by the Federal Act unless that
was the clear and manifest purpose of Congress. Such a pur-
pose may be evidenced in several ways. The scheme of federal
regulation may be so pervasive as to make reasonable the infer-
ence that Congress left no room for the States to supplement
it. Or the Act of Congress may touch a field in which the fed-
eral interest is so dominant that the federal system will be as-
sumed to preclude enforcement of state laws on the same
subject. Likewise, the object sought to be obtained by the fed-
eral law and the character of obligations imposed by it may
reveal the same purpose. Or the state policy may produce a
result inconsistent with the objective of the federal statute. 16
sion affects our analysis, it merely states that conflict preemption applies. In other
words, this 'express preemption' provision simply leads us to a conflict preemption
analysis, which may be applied independently of an express preemption
analysis.").
14. Id. at 261 n.6 (quoting English v. Gen. Elec. Co., 496 U.S. 72, 79 n.5
(1990)); see also Geier v. Am. Honda Motor Co., 529 U.S. 861, 874 (2000) ("We see
no grounds, then, for attempting to distinguish among types of federal-state con-
flict for purposes of analyzing whether such a conflict warrants pre-emption in a
particular case.").
15. 331 U.S. 218 (1947).
16. Id. at 230 (citations omitted). For different views on preemption, see, for
example, Ernest Young, Federal Preemption and State Autonomy, in FEDERAL PREEMP-
TION: STATES' PouTRs, NATIONAL INTERESTS 249, 250 (Richard A. Epstein &
Michael S. Greve eds., 2007). See also Richard A. Epstein & Michael S. Greve, Intro-
duction: Preemption in Context, in FEDERAL PREEMPTION: STATES' POWERS, NATIONAL
INTERESTS 1 (Richard A. Epstein & Michael S. Greve eds., 2007); Richard A. Ep-
stein & Michael S. Greve, Conclusion: Preemption Doctrine and its Limits, in FEDERAL
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I have long believed that field preemption was the proper ap-
proach in light of the comprehensive control that the FDA exer-
cises in issuing warnings about the dangerous side effects and
counter-indications for the use of any drug.17 Efforts to impose
more stringent warnings are best understood as efforts to interdict
a set of uses that the FDA has either expressly or impliedly author-
ized in approving the particular warnings or instructions. The FDA,
for all its flaws, 18 does have one advantage over a system of tort
liability: It makes its judgments on the overall effects of drug use,
not on the particulars of individual cases where the question of
proper warning is compromised in a number of ways.
The ex post tort system makes it difficult to disentangle deci-
sions on the adequacy of a warning from those on causation. All
warnings have to be issued before any particular use is made. To
test the adequacy of a general warning in light of the peculiar cir-
cumstances in an individual case puts far too much emphasis on the
responses of a particular physician or patient when what is needed
is evidence of how the warnings play out in general. It runs a
strong risk of inconsistent verdicts both within and across jurisdic-
tions. The ex post tort approach allows plaintiffs' lawyers to attack
and demoralize FDA scientists in a public forum. It ignores the fact
that the FDA keeps too many drugs off the market. Finally, the
social losses from untreated diseases, however real, are rarely laid at
the FDA's doorstep. In sum, to the extent that a plaintiffs case
relies solely on the inadequacy of the FDA-approved warning, it
should be categorically preempted.
That preemption logic does not extend with equal force to
those decisions about product promotion that take place after the
FDA process has run its course. Suits brought against companies
for activities beyond labeling are not covered by this institutional
argument. Accordingly, cases in which it is alleged that drug com-
panies engaged in fraudulent marketing practices and over-promo-
tion after the release of drugs raise different questions than those
in which a drug company is alleged to have fallen short in its obliga-
PREEMPTION: STATES' PowERs, NATIONAL INTERESTS 309 (Richard A. Epstein &
Michael S. Greve eds., 2007).
17. See Richard A. Epstein, The Case for Field Preemption of State Laws in Drug
Cases, 103 Nw. U. L. Rev. 463 (2009).
18. See Richard A. Epstein, Against Permititis: Why Voluntary Organizations
Should Regulate the Use of Cancer Drugs, 94 MINN. L. REV. 1, 35-40 (2009).
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tions to report adverse incidents to the FDA after the drug is in the
marketplace. 19
The correct substantive position should therefore be to pre-
vent all state law tort attacks. This position should be followed
whether or not one agrees that the FDA is a poor gatekeeper. It
should be followed by those who want to strengthen FDA oversight
of warnings as well as by those, like myself, who would limit the
FDA's power to keep drugs off the market once they have passed
Phase 1 clinical trials-which are relatively inexpensive affairs de-
signed to test basic toXicity.2 0 Put differently, one can concede that
the FDA plays a vital role in patient safety but still think that all
duty-to-warn cases should be preempted when drug manufacturers
comply with existing warnings.
This effort to separate judgments about preemption from judg-
ments about the proper operation of the FDA is, however, not the
current trend. It is a sign of the troubled status of implied preemp-
tion that Seth Waxman, who argued the case for Wyeth, specifically
abandoned his reliance on the field preemption theory on ap-
peal. 2 1 Sadly, his preferred line of conflict preemption lost out as
well. 22 The Food and Drug Administration Amendments Act of
2007 (FDAAA) 23 changed the landscape significantly by allowing
drug companies to update their warnings prior to FDA approval. 24
So Waxman's alternative position might well make sense for new
drugs about which valuable information is often acquired from use,
except that Phenergan has been used in the same way for decades,
ruling out the need for updating. The FDAAA has altered drug
policy for the worse, allowing plaintiffs to challenge drug warnings
at any time. So long as a stricter warning can be imagined, it may
well be for juries to decide whether it should be issued.
19. See Food and Drug Administration Amendments Act of 2007, Pub. L. No.
110-85, 121 Stat. 823 (2007) (codified as amended in scattered sections of 21
U.S.C.) (allowing the FDA to withdraw approval of any drug if its manufacturer
fails to submit the required periodic reports that notify the FDA of adverse drug
events and any other new information that might influence the choice of drug
labeling). Drug manufacturers must revise their warnings as soon as they obtain
reasonable evidence of a serious hazard with drug use. See id.
20. See Epstein, supra note 18, at 19-20.
21. Wyeth v. Levine, 129 S. Ct. 1187, 1192 (2009).
22. See id. at 1204.
23. Pub. L. No. 110-85, 121 Stat. 823 (2007) (codified as amended in scat-
tered sections of 21 U.S.C.).
24. See id. at § 901 (a) (4) (B), 121 Stat. at 924.
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The approach of piling on tort remedies is counterproduc-
tiVe. 25 The implicit premise of this approach, urged most insistently
by David Kessler and David Vladeck, is that tort law has to stand
ready to pick up where the dilatory efforts of the FDA have left
off.2 6 But this is an oversimplification of the basic situation. The
FDA is in a position to commit two equal and opposite sins. In
some instances, it lets dangerous non-prescription drugs on the
market too quickly.27 More ominously, it often keeps drugs off the
market for too long, preventing anyone from using them. 28 The
threat of tort liability does not correct this second type of error.
Rather, tort liability compounds the problem of the FDA's excessive
caution. Unfortunately, Justice Stevens's majority opinion in Wyeth
contains no mention of these offsetting considerations, raised ex-
plicitly in a brief filed on behalf of five distinguished economists,
each well versed in the subject. 29
Catherine Sharkey and Robert Rabin present an intermediate
position, which would give preemptive force to those regulations
that the relevant enforcement agencies believe require it.30 Unfor-
tunately, Justice Stevens did not show much sympathy for that posi-
tion either. Finally, by examining the relative institutional
capacities of regulators and courts, 31 Peter Schuck has sought to
find the "sweet spot" between an implied preemption doctrine that
occupies a field and one that allows all tort actions as a matter of
course. His view of the subject-lying midway between Rabin's and
Sharkey's on the one hand, and mine on the other-is that the
25. See, e.g., Epstein, supra note 17, at 470; Epstein, supra note 18, at 18 (not-
ing that drug companies often delay making new, unapproved drugs available for
fear of tort liability).
26. David A. Kessler & David C. Vladeck, A Critical Examination of the FDA's
Efforts to Preempt Failure-to-Warn Claims, 96 GEO. L.J. 461, 491-95 (2008). Justice
Stevens explicitly relied on their article in Wyeth, 129 S. Ct. at 1203 n.12. For my
futile response to their article, see Epstein, supra note 17, at 468-73.
27. See, e.g., Holly M. Spencer, The RX-to-OTC Switch of Claritin, Allegra, and
Zyrtec: An Unprecedented FDA Response to Petitioners and the Protection of Public Health,
51 AM. U. L. REv. 999, 1000-01, 1030 (2002).
28. See, e.g., Ronald T. Libby, Policy Analysis: Treating Doctors as Drug Dealers:
The DEA 's War on Prescription Painkillers, CATO INSTITUTE, June 16, 2005, available at
http://www.cato.org/pubs/pas/pa545.pdf.
29. Brief ofJohn E. Calfee et al. as Amici Curiae Supporting Petitioner, Wyeth
v. Levine, 129 S. Ct. 1187 (2009) (No. 06-1249).
30. See Robert L. Rabin, Territorial Claims in the Domain of Accidental Harm: Con-
flicting Conceptions of Tort Preemption, 74 BROOK. L. REv. 987, 1000-02 (2009); Cathe-
rine M. Sharkey, What Riegel Portends for FDA Preemption of State Law Products
Liability Claims, 103 Nw. U. L. REv. 415, 437 (2008).
31. See Peter H. Schuck, FDA Preemption of State Tort Law in Drug Regulation:
Finding the Sweet Spot, 13 ROGER WILIAS U. L. REv. 73, 82 (2008).
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passage of the FDAAA, which expanded the FDA's capacity to moni-
tor drugs post-approval, should further tilt the scale to the pro-pre-
emption side of the ledger.32 More regulation reduces the need for
tort actions that cover the same field. Written before the Supreme
Court handed down Wyeth, Schuck's view now also seems to have
been rejected.
My reading of Wyeth is that it largely settles the preemption
debate against preemption: Except in rare situations, my prediction
is that the only protection drug companies can expect from tort
litigation is through congressional action. Justice Stevens slapped
down the 2006 effort by the Bush-era FDA to block tort actions3 3 as
a clear abuse of administrative discretion, including want of any no-
tice-and-comment proceeding. 34 For the purpose of this paper,
however, I wish to focus on a second strand ofJustice Stevens's posi-
tion, chiding the FDA for abandoning its "longstanding position
against the preemptive force of FDA warnings without providing a
reasoned explanation, including any discussion of how state law has
interfered with the FDA's regulation of drug labeling during de-
cades of coexistence." 35 This line echoed the concern of Congress
when it enacted the Food, Drug and Cosmetic Act (FDCA) seventy
years ago, deliberately preserving state law damages claims. 36
In this paper I hope to offer some explanation as to why both
these sentiments misapprehend the relationship between state tort
law and federal preemption. The common wisdom that the FDA
did not urge preemption until its ill-fated 2006 administrative pre-
amble is beyond dispute.37 But I will approach the preemption
question from the opposite direction by asking whether the original
attitude toward preemption should survive in light of the enormous
32. See id. at 83.
33. See Requirements on Content and Format of Labeling for Human Pre-
scription Drug and Biological Products, 71 Fed. Reg. 3922, 3967 (Jan. 24, 2006) (to
be codified at 21 C.F.R. pts. 201, 314, 601).
34. See Wyeth v. Levine, 129 S. Ct. 1187, 1200-01, 1203-04 (2009).
35. Id. at 1201.
36. Brief of Amici Curiae Members of Congress in Support of Respondent at
3, Wyeth v. Levine, 129 S. Ct. 1187 (2009) (No. 06-1249) ("[W]hen Congress en-
acted the FDCA 70 years ago, it deliberately preserved state-law damages claims.
Since that time, Congress has consistently understood that federal law does not
preempt state-law failure-to-warn claims with respect to drugs approved by the
FDA. This understanding has been fortified by settled practice under the statute.
For decades, innumerable state-law actions involving FDA-approved pharmaceuti-
cals have been prosecuted to final judgment or settlement.").
37. See Victor Schwartz et al., Marketing Pharmaceutical Products in the Twenty-
First Century: An Analysis of the Continued Viability of Traditional Principles of Law in the
Age of Direct-to-Consumer Advertising, 32 HARV. J.L. & PUB. POL'Y 334, 385 (2009).
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changes that occurred during this formative period of tort law prior
to its vast expansion after the passage of the Second Restatement of
Torts. Put simply, context matters. Preemption makes perfect
sense against the backdrop of tort law as it was formulated in 1939,
right after the 1938 FDCA added requirements dealing with
safety, 38 through the 1962 Kefauver-Harris Amendments that con-
ferred on the FDA the power to examine the effectiveness of ques-
tionable drugs.39 This article reinterprets the peaceful coexistence
between tort law and the FDA as a function of the narrow and sensi-
ble content of the earlier tort law, which has been undermined by
substantive state law developments over the last forty years.
Even the most ardent defender of field preemption would find
nothing in the tort law before 1965 that could ever collide with the
commands of the FDA. To show this, the next section traces the
evolution of both duty-to-warn and design-defect products liability
cases. The huge expansion of state products liability law immedi-
ately followed the adoption of the Second Restatement of Torts in
1965, with its famous, but modest, strict liability provision in Section
402A.40  This expansion has put strains on the law that are
powerfully exhibited by the facts in Wyeth and other modern cases,
including Colacicco. Section I of this paper shows the absence of
conflicts between tort law and FDA policy prior to 1965. Section II
explains why modern tort law placed the two on a collision course
in cases like Wyeth. Section III explains how the distortions in Ver-
mont tort law (which governed in Wyeth) pose real threats to the
operation of the federal system and require a rejection of the posi-
tion of the Wyeth majority decision of Justice Stevens. Section IV
explores the post-Wyeth landscape through the lens of Colacicco.
II.
PRE-1965 PRODUCTS LIABILITY LAW41
Products liability law began in restrictive fashion with the 1842
English decision in Winterbottom v. Wright,42 which arose out of an
38. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 (1938).
39. See Drug Amendments of 1962, Pub. L. No. 87-781, § 102(d)-(e), 76 Stat.
780, 781-82 (1962) (codified as amended in scattered sections of 21 U.S.C.).
40. RESTATEMENT (SECOND) OF TORTS § 402A (1965) (introducing strict liabil-
ity regime).
41. I have given a longer treatment of these issues in RICHARD A. EPSTEIN,
MODERN PRODUCTS LIABILITY LAW 9-35 (1980) [hereinafter Epstein, MODERN
PRODUCTS LIABILITY LAW]. I have also addressed many of these issues in Richard A.
Epstein, Why the FDA Must Preempt Tort Litigation: A Critique of Chevron Deference and a
Response to Richard Nagareda, 1 J. TORT L. 1 (2006).
42. 152 Eng. Rep. 402 (1842).
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action brought by an injured driver of a defective coach against the
coach repairman. There was no direct contractual relationship be-
tween the plaintiff and the defendant, and the lack of privity
blocked the action without regard to any causal relationship be-
tween the defect introduced by defendant's repairs and the injury
to the plaintiff.
In reality, the outcome was not quite as strange as the common
denunciations-Prosser described the decision as "a fishbone in
the throat of the law"43-might suggest. However, Prosser's argu-
ments are manifestly incorrect. First, he contends that "nothing is
more foreseeable than that [goods] will be resold to a consumer,
or, if they are dangerously defective that he will be injured by
them. '44 But the resale of goods with possible defects is equally
foreseeable to a plaintiff, so the question is what allocation of risk
minimizes total accident costs when each party can foresee errors
by the other. Foresight there may be, but its relationship to liability
is left unexplained. His second argument is little more than a re-
phrase of the first: "[H] e has so dealt with the goods that they are
likely to come into the hands of another, and to do harm if they are
defective." 45 This suppresses reference to the mechanism of causa-
tion and the knowledge of intermediate parties and product users,
both of which could well matter. A complete analysis should ask
whether the plaintiff might have an action against his employer for
his failure to supply a safe place of work, and what should happen if
the defendant had been released from potential liability under his
contract with the Postmaster General. Winterbottom could be read as
an effort to give priority of place to downstream control or to free-
dom of contract principles. But both points were generally ignored
in the subsequent evolution of the doctrine.
Be that as it may, it was quite clear that the privity defense had
fully evaporated by the time of the 1938 FDCA. The key landmarks
are well known, but the Act's overreliance on foresight has always
escaped the criticism it deserves. This critique rests on two related
themes. The first theme is that intentional harms by concealment
or deliberately mislabeling can be a source of liability. The second
is that parties have a differential capacity to avoid risk. In all cases,
the conduct of both the plaintiff and third parties matters.
43. W. PAGE KEETON ET AL., PROSSER AND KEETON ON TORTS § 96 (5th ed.
1984).
44. Id.
45. Id.
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Both of these themes are evident in Thomas v. Winchester,46
which carved out the first exception to the privity limitation for un-
reasonably dangerous products. In modern terminology, Thomas
was a mislabeling case where a druggist sold the poison belladonna
in a bottle that was labeled as extract of dandelion, a harmless sub-
stance. The issue of negligence seems trivial, for no careful person
would confuse the two substances. But any supposed causal compli-
cations were eliminated because the plaintiff had taken the bella-
donna from its original container in reliance on the label. Liability
followed because no one thought that she would have taken the
drug if she had known the true state of affairs.
This pattern of bad defendant/good plaintiff carried over into
the twentieth century. In Kuelling v. Roderick Lean Manufacturing
Co.,47 the plaintiff was injured when he hitched to his team of hor-
ses a defective roller he had acquired from a dealer who purchased
it from the defendant. The defendant knew the wood was defective
and concealed the defect with putty. Neither the plaintiff nor the
dealer was aware of the defect. This is worse than Thomas v.
Winchester, even if the poison was inherently dangerous and the
roller imminently dangerous because badly made. The modern
analogy to Kuelling would be deliberately putting poison in a
container that supposedly contained medicine.
MacPherson v. Buick Motor Co.48 is commonly read to mark the
demise of the privity defense. It held that plaintiffs could sue auto-
mobile manufacturers in negligence if the wheels were made of de-
fective wood that caused damage in ordinary use.49  The
description offered by Judge Cardozo simply stated that "while the
plaintiff was in the car, [the wheel] suddenly collapsed" because it
was made of defective wood.5 0 From this description, there may be
a coherent principle that allows for, but limits, the scope of prod-
ucts liability. The product was defective in its original position, the
defect was latent, and the plaintiff and all third parties had used it
in normal and proper condition. To be sure, this case is more diffi-
cult than Kuelling where the active concealment of the defect
turned the case into one of asymmetrical information. It is easy to
impose liability on the party with knowledge of the risk; but, in Mac-
Pherson, the shift to negligence rests on a (defensible) judgment
that the defendant is in a better position to avoid the risk through
46. 6 N.Y. 397 (1852).
47. 75 N.E. 1098 (N.Y. 1905).
48. 111 N.E. 1050 (N.Y. 1916).
49. See id. at 1053.
50. Id. at 1051.
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various techniques of quality control (including systems of
inspection).
Yet there are two gaps in Cardozo's opinion, one of fact and
the other of law. On the former, a careful study by Professor Hen-
derson exploded the myth that this wheel suddenly broke without
explanation. Rather, this Buick car, which had been used to haul
concrete, had its wooden wheel break when the plaintiff, while driv-
ing thirty miles per hour, sought to turn after sinking into four in-
ches of gravel. 51 That level of downstream misuse was so acute that
this plaintiff would have had a hard time winning before ajury even
under today's law.
The second gap is conceptual. Cardozo's opinion has an odd
juxtaposition of narrow and broad justifications. He explains that:
"We are dealing now with the liability of the manufacturer of the
finished product, who puts it on the market to be used without in-
spection by his customers. If he is negligent where danger is to be
foreseen, a liability will follow." 52 The first sentence is quite narrow
and follows the pattern of harms caused by latent defects in prod-
ucts subject to ordinary use. The asymmetry between the parties
that justifies liability is the greater capacity to avoid harm through
inspection, which the customer need not do precisely because the
manufacturer has done it. The second sentence turns on foresight,
and the potential scope of liability that could be much broader
when that notion is, as happened, wrenched out of its narrow con-
text. But foresight is a useless tool in all these cases: If the defen-
dant can foresee danger from defects, so too can the plaintiff. If
the defendant can foresee product misuse by the plaintiff, the
plaintiff can see subpar product manufacturing by the defendant.
The issue is not what can be foreseen. The issue is what steps each
party should be expected to take so that when they act together
losses are minimized. On that score, the individual plaintiff could
have superior access to information because he has knowledge of
both the product and the context in which it is being used-a fact
which looms large in many cases.
This issue of downstream knowledge looms large in the next
major case, Escola v. Coca Cola Bottling Co. 53 In his famous concur-
rence, Justice Traynor indicated that he would have applied strict
51. James Henderson, Jr., MacPherson v. Buick Motor Company: Simplifying
the Facts While Reshaping the Law, in TORTS STORIES 45-46 (Robert L. Rabin & Ste-
phen D. Sugarman eds., 2003).
52. MacPherson, 111 N.E. at 1053.
53. Escola v. Coca Cola Bottling Co. of Fresno, 150 P.2d 436 (Cal. 1944).
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liability when an exploding Coca Cola bottle injured the plaintiff.54
Once again, the majority's statement of the facts makes it appear
that the explosion 'Just happened," but the prospects for down-
stream misuse were manifold: The record revealed that the distribu-
tor had placed the bottles behind the counter for thirty-six hours
before the plaintiff picked them up, only to have one explode in
her hand. Her coworker testified that she had not banged the bot-
tle.5 5 We do not know, of course, whether the testimony was true or
rehearsed. But even if that testimony were 100 percent accurate,
the downstream risks are not eliminated. In other explosion cases,
the bottle could be mishandled during distribution, which could
create liability, although likely in negligence. Or an explosion
could result from a sharp tap on the edge of a sound bottle that has
been left to sit in the sun. If the distributor had failed to exercise
reasonable care, liability could follow under res ipsa loquitur if it
could be shown that the bottle was safe when it reached the distrib-
utor and promptly exploded when unloaded. That theory of liabil-
ity (even if the distributor was the same party as the manufacturer)
would have rendered irrelevant Traynor's disquisition on why strict
liability is appropriate for manufacturers. 5 6 Likewise, if there was
product misuse by the end user-and there were alleged fraud
rings for these bottle cases at the time-Justice Traynor would have
rightly denied recovery because the product did not cause damage
in its "normal and proper" use.
5 7
What is most important about the case is not the broad state-
ment of "public interest" rationales, but the narrow content of the
strict liability rule: "The manufacturer's liability should, of course,
be defined in terms of the safety of the product in its normal and
proper use, and should not extend to injuries that cannot be traced
to the product as it reached the market."58 Escola thus makes ex-
plicit two limitations on tort liability that were also present in Car-
dozo's MacPherson decision. First, the product must be in its
original condition, which, by implication, means that no third party
altered the product. Second, the product must have been used in
its normal and proper way; the original manufacturer whose prod-
54. See id. at 440 (Traynor, J., concurring).
55. Id. at 437-38 (Gibson, C.J.).
56. See id. at 440-44 (Traynor, J., concurring).
57. I cannot trace down the oral references to this effect that I heard years
ago in California, but the prospects can never be dismissed. For the detailed expo-
sure of the fraud rings that undermined the California workers' compensation law,
see Gary T. Schwartz, Waste, Fraud and Abuse in Wor*ers' Compensation: The Recent
California Experience, 52 MD. L. REv. 983, 987-92 (1993).
58. Escola, 150 P.2d at 444 (Traynor, J., concurring).
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uct was safe in its original condition drops out of the case once a
misuse has taken place.
Interestingly, while Justice Traynor offers reasons why strict lia-
bility provides a simpler and more powerful rationale than negli-
gence, he does not utter a syllable to explain either of the two
limitations he adds. It is, however, possible to supply the missing
rationale, but only by dispensing with the foresight reasoning. A
sensible social welfare function in torts cases starts with the aware-
ness that there is sequential control over a dangerous instrumental-
ity, where each person handles it out of the sight of others. The
parties can, through intermediaries, adjust their price to reflect the
risk. The task, therefore, is to find an efficient but general way to
describe what each party is entitled to expect of the other. The
usual language of "reasonable expectations" is often attacked as cir-
cular, and thus unequal to the task in this area as in others. 59 As
the argument goes, the only way one can use reasonable expecta-
tions to determine what the law is, is to first know the law.
In fact, that facile argument is incorrect. The right way to ap-
proach the problem is to ask, in this sequential game, which steps
taken by both parties will minimize social loss-here defined as the
sum of accident costs and their prevention, including the costs of
litigation. Reasonable expectations set out a pattern whereby if
both sides comply, no accidents will happen. Traffic rules do the
same thing, for no intersection collisions will occur if all parties fol-
low the rules of the road. The hard issues arise when one side devi-
ates and some other party (the plaintiff or a third person) has to
decide without notice what to do in response. In a highway acci-
dent, the party who has the last clear chance, i.e., knows of the
peril, must take prudent steps to react to the new burst of relevant
information. 60 The harder question is whether he can recover for
the costs of those precautions in the absence of injury.61 In the
59. One example is the use of reasonable expectations in Fourth Amendment
law. See, e.g., Lucas v. South Carolina Coastal Council, 505 U.S. 1003, 1035 (1992)
(Kennedy, J., concurring); Katz v. United States, 389 U.S. 347, 358-59 (1967). I
have tackled this issue in Richard A. Epstein, Privacy, Publication, and the First
Amendment: The Dangers of First Amendment Exceptionalism, 52 STAN. L. Riv. 1003
(2000), and Richard A. Epstein, Lucas v. South Carolina Coastal Council: A Tan-
gled Web of Expectations, 45 STAN. L. REV. 1369 (1993).
60. See, e.g., RESTATEMENT (SECOND) OF TORTS §§ 479-80 (1965); Donald Witt-
man, Optimal Pricing of Sequential Inputs: Last Clear Chance, Mitigation of Damages, and
Related Doctrines in the Law, 10J. LEGAL STUD. 65, 78-82 (1981).
61. See Susan Rose-Ackerman, Dikes, Dams, and Vicious Hogs: Entitlement and
Efficiency in Tort Law, 18 J. LEGAL STUD. 25, 26 (1989) (advocating for a rule that
allows for the recovery of costs taken to avoid actionable harm).
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road case, it means that one driver has to get out of the way if the
other crosses over into his lane. In the products liability context, it
means that a consumer who knows that there are worms in a candy
bar cannot eat it and then sue for damages 62-a decision that coin-
cidentally came down in 1962, the year of the Kefauver Harris
amendments.
The impact of the early innovations in products liability law
was to treat the two parties as though they were in direct contact
with each other. Some measure of the cautious attitude regarding
these developments is gleaned from Pease v. Sinclair Refining Co.,63
decided in 1939. The plaintiff was a science teacher injured in an
explosion that occurred when he placed a substantial amount of
sodium in water, causing the loss of an eye and serious burns. The
plaintiff knew well the dangers of mixing sodium with water, but he
put the concoction together because the water was from a bottle
marked kerosene. The defendant oil company had marked it as
such in order to allow its shipment through the mails. The plaintiff
relied on the label and did not smell the bottle. After an extensive
trial, the jury found the defendant guilty of negligence and the
plaintiff free of contributory negligence. 64 As a sign of the times, it
took an appellate decision by Chief Judge Clark to establish that it
was proper to leave the questions of both negligence and contribu-
tory negligence to the jury.
What is striking is how easy the case should have been for the
plaintiff. The defendant misled the plaintiff, who had a right to
rely on the label. That deliberate misrepresentation did not lose its
sting because the defendant clearly had no intention to harm the
plaintiff. It was quite enough that it disarmed the plaintiffs well-
honed instincts for safety. Today, liability is too certain for a paral-
lel case to get within miles of a jury, except perhaps for punitive
damages for reckless disregard of safety. 65 It takes little imagination
to ask what would have happened if the fluid which had been misla-
beled to facilitate shipping was supposed to be used as a drug for
medical treatment.
62. See Kassouf v. Lee Bros., 26 Cal. Rptr. 276, 278-79 (Dist. Ct. App. 1962)
(using assumption of risk to achieve that result).
63. 104 F.2d 183 (2d Cir. 1939).
64. See id. at 184-85.
65. For a modern view on punitive damages, see State Farm Mutual Auto. Ins.
Co. v. Campbell, 538 U.S. 408, 416-28 (2003) (reviewing constitutional require-
ments for punitive damages).
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The issue in Pease regarded a danger that was latent on one
side and patent on the other. Campo v. Scofield66 encompassed the
exact opposite pattern of risk, one that was open and obvious to the
product user. The facts were simple enough: The plaintiff caught
his hand in the revolving rollers of an "onion topper," where they
were badly mangled. Judge Fuld stressed that the obviousness of
the defect put the user in a position to decide how best to use it:
"[I] f the machine is without any latent defect, and if its functioning
creates no danger or peril that is not known to the user, then the
manufacturer has satisfied the law's demand. '67 Note that this de-
fense blocks not only the duty-to-warn claim-why impose a duty to
tell someone what he already knows-but also the design defect
cause of action. The logic of the position is that full information
allows downstream parties to decide whether, and if so how, to use
the product in question. The threat of personal injury to the user,
and the prospect of workers' compensation payments for the em-
ployer, will lead to a selection of equipment suitable for its in-
tended purposes. The clear logic behind this decision is that the
downstream users are in a position to customize any equipment in
ways that meet their respective demands. And once they do, the
equipment is no longer in its original condition, so that liability for
the manufacturer ceases on the ground that the "[t]hing used was
not the thing sold."68 Supply full information and the logic flips
over from Pease to Campo. Information allows the party that pos-
sesses it to organize the efforts that reconcile the conflicting de-
mands of output and safety. And the temptation to redesign
equipment to fight the last war is ruled out on categorical grounds
because the defendant gets summary judgment on both warning
and design theories of liability.
This attitude toward risk was reflected in the "open and obvi-
ous" defense in design defect cases. In Evans v. General Motors,69 the
decedent was killed when his GM car was broadsided. The court
refused to allow a negligence case based on a crashworthiness the-
ory by pointedly refusing to extend liability "despite the manufac-
turer's ability to foresee the possibility" of collision.70 Once again,
the transfer of full information properly precluded the plaintiff
from moving back along the chain of distribution. Joint causation
66. 95 N.E.2d 802 (N.Y. 1950).
67. Id. at 804.
68. See Young v. Aeroil Prods. Co., 248 F.2d 185, 190 (9th Cir. 1957).
69. 359 F.2d 822 (7th Cir. 1966).
70. Id. at 825.
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theories of liability for successive liability, so critical in Wyeth, were
not used in these full information settings. 71
These cases give an accurate description of the state of the law
at the time of the Second Restatement of Torts in 1965.72 So long
as liability was confined to latent hazards, the preemption issues of
later times are just not implicated. But the once-solid distinction
between patent and latent defects was crumbling. A famous pas-
sage in the Fowler Harper and Fleming James treatise argued
strongly against the open and obvious rule, claiming that obvi-
ousness should count as only one factor in a general negligence
equation. 73 They did not think of their work as particularly revolu-
tionary, but by taking a huge category of cases from the land of
defendant summary judgments into hotly contested jury trials, it
surely was.
This widespread academic ferment led some manufacturers to
do what they had never contemplated before. Sensing they would
be held responsible for losses that were better controlled at the
downstream level, they started to insert contractual provisions
where tort law had started to turn wobbly, including of course the
limited liability provisions at issue in Henningsen v. Bloomfield Mo-
tors.7 4 But this tactic failed under both contract and tort law. Dis-
claimers of warranties were effectively banned under the Uniform
Commercial Code, 75 and their role was sharply limited in much-
celebrated cases that dealt with implied warranties 76 or strict liabil-
71. There could clearly be some argument as to whether these cases merit the
description "full information." The use of the term "open and obvious" was in-
tended to make liability turn on what was publicly known so as to avoid the risk of
perjured defenses of the sort that denied the existence of that knowledge. In fact,
the single most important feature about automobile safety, weight, is well known.
To require perfect awareness of all that follows from an open and obvious condi-
tion clearly makes it impossible to accept any argument of that sort.
72. RESTATEMENT (SECOND) OF TORTS § 402A (1965).
73. See 2 FOWLER V. HARPER & FLEMING JAMES, JR., THE LAW OF TORTS § 28.5
(1956) ("[T]he bottom does not logically drop out of a negligence case against the
maker when it is shown that the purchaser knew of the dangerous condition.").
74. Henningsen v. Bloomfield Motors, Inc., 161 A.2d 69, 74 (N.J. 1960) (find-
ing disclaimers unconscionable in implied warranty case brought by
nonpurchasers of the product).
75. See, e.g., U.C.C. § 2-318 (1995) (stating that a "seller may not exclude or
limit the operation of this Section"); U.C.C. § 2-719(3) (holding that a limitation
on "consequential damages for injury to the person in the case of consumer goods
is prima facie unconscionable," without indicating any way in which that presump-
tion could be rebutted).
76. See Henningsen, 161 A.2d at 74.
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ity in tort.77 At this point, contractual correction of judicial errors
was no longer possible. The judges who failed to appreciate the
importance of downstream conduct effectively froze the law in the
wrong place for the wrong reasons.
The Second Restatement is better viewed as a consolidation of
earlier trends than the adumbration of the impending transforma-
tion of the law. 78 In its original formulation, the movement to strict
liability did not dislodge any of the constraints on downstream con-
duct that Judge Traynor thought were an integral part of his strict
liability rule.79 The definition of "product defect" makes it clear
that the strict liability rule "applies only where the product is, at the
time it leaves the seller's hands, in a condition not contemplated by
the ultimate consumer, which will be unreasonably dangerous to
him. '80 On the flip side, the doctrines of contributory negligence
and assumption of risk hold that:
Contributory negligence of the plaintiff is not a defense when
such negligence consists merely in the failure to discover the
defect in the product, or to guard against the possibility of its
existence. On the other hand the form of contributory negli-
gence which consists in voluntarily and unreasonably proceed-
ing to encounter a known danger, and commonly passes under
the name of assumption of risk, is a defense .... 81
At this point, the one question that matters is whether any
form of liability that was contemplated either in negligence or strict
liability could pose the slightest threat to the way pharmaceutical
companies made or marketed their products under these early
rules. The answer has to be an emphatic "no." It therefore made
perfect sense for many statutes to have a clause that saved common
law causes of action-and why not, when such actions clearly reach
only issues that fly beneath the radar of these statutory schemes?
Cases of mislabeling and defective preparation are open and
shut as to liability today and nothing about the ill-fated 2006 FDA
preamble was meant to alter what has become a hard and fast rule.
Deviate from the standards of purity or make a mistake in labeling
and your goose is cooked. Meet standards on purity and labeling
77. See, e.g., Greenman v. Yuba Power Prods., Inc., 377 P.2d 897, 901 (Cal.
1963) (approving the "refusal [of the law] to permit the manufacturer to define
the scope of its own responsibility for defective products" by contract).
78. For a review of the narrowness of its rules, see Epstein, MODERN PRODUCTS
LuABILITY LAW, supra note 41, at 57-67.
79. See supra text accompanying note 58.
80. RESTATEMENT (SECOND) OF TORTS § 402A cmt. g (1965).
81. Id. cmt. n.
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and you are home free. The responsibility now moves downstream
to subsequent actors. Rightly understood, the simple explanation
for the state of play between the regulatory system of 1939 and the
tort system of that date is that they do not come into conflict. To
say that there was peaceful coexistence between the two is correct,
but only in a highly restricted sense. The critical but modest aspira-
tions of the early tort law assured that never a conflict, never an
overlap, never an occupation of a field could arise. It therefore
made perfectly good sense to insert in federal statutes provisions
creating express preemption on the one hand and common law
savings clauses on the other. For example, the National Traffic and
Motor Vehicle Safety Act of 196682 contained both an express pre-
emption clause 3 and a savings clause providing that "[c] ompliance
with" a federal safety standard "does not exempt any person from
any liability under common law." 84
Just two years later, tort liability experienced a vast expansion
in the series of crashworthiness cases initiated by Larsen v. General
Motors Corp.8 5 In the pre-Larsen environment, it is incorrect to say
that the question of preemption did arise and that it was resolved in
favor of allowing the private right of action. In the post-Larsen envi-
ronment, however, the conflict became acute. This was shown in
the case of Geier v. American Honda Motor Company,8 6 where Justice
Breyer, over a Justice Stevens dissent, allowed for federal preemp-
tion after exhaustively reviewing the complex negotiations that led
to a postponement of the introduction of air bags into passenger
vehicles.8 7 In effect, his views of preemption did not block any
common law product liability actions of the sort maintained before
1965, of which Geier was surely not one. Justice Breyer treated Geier
as a case of conflict preemption, but it could have been decided as
easily as a case where tort liability frustrated a coherent federal
scheme or where the active intervention of the Department of
82. Pub. L. No. 89-563, 80 Stat. 718 (1966) (repealed 1994).
83. § 103(d), 80 Stat. at 718, 719 ("Whenever a Federal motor vehicle safety
standard established under this subchapter is in effect, no State or political subdivi-
sion of a State shall have any authority either to establish, or to continue in effect,
with respect to any motor vehicle or item of motor vehicle equipment, any safety
standard applicable to the same aspect of performance of such vehicle or item of
equipment which is not identical to the Federal standard.").
84. § 108(c), 80 Stat. at 718, 723.
85. 391 F.2d 495 (8th Cir. 1968).
86. 529 U.S. 861 (2000).
87. See id. at 874-81.
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Transportation occupied the field.88 In any event, Geier represents
the type of case that could not have survived summary judgment
before the advent of the crashworthiness cases. In closing, I know
of no litigated case in the pre-1965 period in which the court
should have found preemption under any of the three established
doctrines.
III.
PRODUCTS LIABILITY LAW IN ITS MODERN VOICE
The shift in the basic thrust of products liability came in the
immediate aftermath of the Second Restatement. Most critically,
the massive expansion of tort liability in products liability cases had
little to do with the strict liability innovations of Section 402A.
Strict liability provisions proved relevant in the cases where they
were hardly needed, namely those dealing with manufacturing de-
fects built into the product before it leaves the manufacturer's
hands.8 9 The manufacturer's complete control over the fabrication
process, including the capacity to impose quality control standards
and inspections, makes it wise to dispense with the use of a negli-
gence inquiry, which even in the pre-1965 period was hurried along
by a generous dollop of res ipsa loquitur.90
Yet the design and warning cases present entirely different is-
sues precisely because the passing down of full information no
longer created a shield against liability. The decision to expand
liability did not, of course, undercut the traditional product liability
cases for latent defects that caused harm in ordinary use. Those
cases became so easy (and with good quality control, so rare) that
they quickly disappeared, as it became truly hopeless to contest lia-
bility. But the pre-1965 pressure to push responsibility down the
chain of distribution toward the user came to a halt with the abro-
gation of the open and obvious rule.
The change was first felt in the design defect area when the
courts quickly moved away from the position that concentrated
88. See id. at 873-74 (discussing the ways in which various models of preemp-
tion might apply).
89. See, e.g., Moore v. Jewel Tea Co., 253 N.E.2d 636, 647 (Ill. App. Ct. 1969)
(requiring plaintiff to prove that her injury resulted from a condition of the prod-
uct which was unreasonably dangerous and which existed at the time the product
left the manufacturer's control).
90. See Escola v. Coca Cola Bottling Co. of Fresno, 150 P.2d 436, 440 (Cal.
1944) (Gibson, C.J.) (affirming the judgment below in reliance on the res ipsa lo-
quitur formulation, which applied once it was clear that the downstream users did
not alter the product).
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solely on latent defects by adopting the Harper and James view9 1
that even if a condition was open and obvious to the user, some
duty could exist on the part of the manufacturer to guard against it.
Micallef v. Miehle Co. 9 2 unceremoniously overruled Campo by treat-
ing all accidents arising from the use of machine tools as raising
hard questions of joint causation. The downstream parties may
have incurred some responsibility, but the initial supplier of the
product remained a "substantial factor" in the mix even if foolish
things were done downstream. 93
Similarly, theories of joint causation in the crashworthiness
area displaced the downward pressure of the open and obvious
rule. Thus, in the watershed case of Larsen,94 the decisive question
now was what design features the defendant had to install to deal
with the anticipated misbehavior of the plaintiff,95 which could in-
clude driving drunk at over one hundred miles per hour.96 Once
again, any foreseeable injury was sufficient to trigger the manufac-
turer's duty, while the knowledge of the condition of the vehicle by
the driver necessarily became a secondary issue. And once again
the expansion of liability came under the negligence rubric, given
that the manufacturer was "under a duty to use reasonable care in
the design of its vehicle to avoid subjecting the user to an unreason-
able risk of injury in the event of a collision."97 Sharp boundary
conditions and joint causation displaced the relatively sharp separa-
tion of responsibilities under the open and obvious rule.
The new developments did not necessarily displace the older
tests that tied liability to the reasonable expectations of product
users. Indeed, the critical decision in Barker v. Lull Engineering Com-
pany,98 expressly preserved a reasonable expectations strand of
product liability when it articulated this two-pronged test for prod-
uct liability:
[W] e have concluded from this review that a product is defec-
tive in design either (1) if the product has failed to perform as
safely as an ordinary consumer would expect when used in an
intended or reasonably foreseeable manner, or (2) if, in light
91. See HARPER &JAMES, supra note 73.
92. 348 N.E.2d 571, 573 (N.Y. 1976) ("The time has come to depart from the
patent danger rule enunciated in Campo v. Scofield .....
93. See id. at 575.
94. Larsen v. General Motors Corp., 391 F.2d 495 (8th Cir. 1968).
95. See id. at 501.
96. See LeBouef v. Goodyear Tire & Rubber Co., 623 F.2d 985, 989 (5th Cir.
1980).
97. Larsen, 391 F.2d at 502.
98. 573 P.2d 443 (Cal. 1978).
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of the relevant factors discussed below, the benefits of the chal-
lenged design do not outweigh the risk of danger inherent in
such design. In addition, we explain how the burden of proof
with respect to the latter "risk-benefit" standard should be
allocated.99
The first prong of this test keeps alive, in somewhat expanded
form, the noncontroversial approach to product liability cases deal-
ing with latent defects. But the second prong opens up vast new
vistas of liability (which the Barker court might not have fully appre-
ciated) that notably undermine the old approach to sequential con-
duct in full information settings.
Specifically, Barker involved a high-lift loader designed for work
on level ground. The product manuals stated explicitly that it
should not be used on uneven terrain, where more complex equip-
ment was required. The plaintiff, a substitute driver with limited
experience in using such equipment, was hurt when he fell from
the loader. The regular driver was smart enough to call in sick.
The plaintiffs case rested on the claim that the loader should have
been designed in ways that would prevent this injury, such as in-
cluding outriggers to provide greater lateral stability. 100 The origi-
nal jury refused to find for the plaintiff, and the case was remanded
on the ground that the instructions did not take into account the
manufacturer's need to guard against foreseeable misuse, even
when the risks in question were obvious to all concerned. 10 1
Barker's entire framework resulted in a vast misalignment of le-
gal responsibility because the real breakdown in the system oc-
curred at the worksite level where liability, perhaps under workers'
compensation, should apportion the loss. The employer had full
information as to the limits of the machine, and the plaintiff may
have had it as well. If he did not, we know who was in the better
position to communicate the needed information to the worker.
But to require this loader-and by implication, every loader-to be
designed for uneven terrains, would make it impossible to adopt
efficient segmentation of worksite equipment. The decision im-
poses a heavy tax on anyone who makes a cheaper loader that is
proper in most situations simply because they can be misused in
settings where they are unsafe. The price will increase, use will dry
up, and older equipment will remain in service longer than it
should.
99. Id at 446.
100. See id. at 447-48.
101. See id. at 449.
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To reach this misguided result, Judge Tobriner had to deny
the exclusive application of the reasonable expectations test, under
which the efficient solution requires each party to do its part. To
do so, he appealed to an influential article by John Wade that in-
sisted a consumer expectations test could never set the exclusive
standard for liability: "In many situations ... the consumer would
not know what to expect, because he would have no idea of how
safe the product could be made." 10 2 But Wade asked the wrong
question. The issue for the consumer or product user is not what
else is on the market, but rather what steps to take in deciding
when and how to use the equipment at hand. By that standard,
there was no information gap in Barker, where it was painfully ap-
parent that the loader was not designed for use on rugged terrain.
Of course, additional design features found in other loaders could
have been added, but only in ways that would render the loader less
useful.
At this point, the twin sins of the expanded scope of products
liability law become clear. First, because reasonable expectations
do not do the entire job, the jury is allowed, with the benefit of
hindsight, to conduct its own cost-benefit analysis of the product
design. The temptation to overrate the risk that did occur, as op-
posed to those that might have occurred in other settings, is mani-
fest, and it increases the prospect of inconsistent jury decisions in
response to alternative hazards. Second, that judgment on product
design is not made on the expectation that the product user will
make normal and proper use as under the Escola formulation. In-
stead the rule is that the design must also cover cases where the
product is used in an "intended and reasonably foreseeable man-
ner,"10 3 which includes all sorts of misuses against which it is possi-
ble to guard, but only at a cost. The effect of this rule is to impose a
tax on the prudent to protect the foolish. No longer is it permissi-
ble to narrow the scope of use to make the equipment more effi-
cient for its intended function. Downstream managers and
professionals are now being treated as though they will misbehave,
which only increases their incentives to do so. 10 4 The dangers of
departing from a full information model, under which the sole duty
is to let downstream users know what is expected of them, condi-
tional on the product manufacturer delivering what he has prom-
102. Id. at 454 (citing John Wade, On the Nature of Strict Tort Liability for Prod-
ucts, 44 Miss. L.J. 825, 829 (1973)).
103. See, e.g., Barker, 573 P.2d at 443.
104. See Richard A. Epstein, Products Liability as an Insurance Market, 14J. LE-
GAL STUD. 645, 653-54 (1985).
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ised to do, are manifest. The dominant theme is to substitute
inefficient upstream precautions for efficient downstream ones,
and the seeds are planted for Wyeth v. Levine.
The revolution behind these post-1965 design defect cases is
matched by a parallel revolution in the duty-to-warn cases that is
directly relevant to pharmaceutical cases. A fair reading of the pre-
1965 cases is that, as in Pease v. Sinclair, once the product was prop-
erly identified, additional obligations to warn were modest.10 5 Poi-
sons had to be labeled as such, but the labeling of most medicines
rarely, if ever, generated any form of potential liability. The sim-
plest explanation is two-fold. For widely disseminated generic prod-
ucts, finding information is relatively easy. And in any event, with
respect to prescription drugs, the patient can rely on the profes-
sional knowledge of the physician to steer clear of trouble on pain
of possible malpractice liability. Clearly this picture has some ele-
ment of tension in it because many dangers from the use of
medicine are not discoverable by ordinary inspection. Therefore,
there would be no objection to statutes requiring certain products
to be labeled before sale, which was also the case in the pre-1965
period.10 6 Explicit warnings, provided in advance, could be re-
quired for the sale of drugs to close any remaining information gap.
There was some modest expansion of warning liability in the Sec-
ond Restatement, bridging the gap between old and new: "Likewise
in the case of poisonous drugs, or those unduly dangerous for other
reasons, warning as to use may be required." 10 7 But even that cau-
tious sentiment does not translate into the huge expansion of duty-
to-warn liability against manufacturers, which, under modern law,
uses a fine-toothed comb to go through every nook and cranny of
ever-long warnings.
In a fashion that was largely unanticipated, the law soon spilled
over beyond the narrow confines of the Second Restatement. Early
landmarks in this transformation were the 1968 case of Davis v. Wy-
eth Laboratories,10 8 followed by Reyes v. Wyeth Laboratories,1° 9 which
took the position that there was a duty to disclose a less than one-in-
a-million chance that a polio vaccine could cause polio.1 10 One
105. See supra text accompanying notes 63-65.
106. See, e.g., Osborne v. McMasters, 41 N.W. 543, 543 (Minn. 1889) (requir-
ing a label that said "poison").
107. RESTATEiENr (SECOND) OF ToRTs § 402A cmt. j (1965).
108. 399 F.2d 121 (9th Cir. 1968).
109. 498 F.2d 1264 (5th Cir. 1974).
110. See Davis, 399 F.2d at 124 (quoting a report from the Surgeon General:
"The level of this risk can only be approximated but clearly is within range of less
than I [sic] case per million doses. Since the cases have been concentrated among
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possibility in both these cases was to insist that the duty to warn
rested with the party who administered the drugs in the first in-
stance-a pharmacist in Davis 1' and a registered nurse in
Reyes' 12-neither of whom passed specific information onto their
respective plaintiffs.
In a sense, it was easy to find liability since the vaccines were
administered without any warning to the patient. The issue of the
warning's adequacy did not have to be assessed. But the stress on
upstream control of the warning process comes at a real cost. The
risks in question are generic, so other sources of information are
available about them. And it is risky business to insist on the disclo-
sure of a downside risk without being sure that the far greater risk
of getting polio from a wild strain is disclosed as well. As a simple
matter of fact, the odds were overwhelming that the wild strain, and
not the vaccine, caused the injury in light of the epidemic of polio
at that time. 1 3 The net effect of judicial intervention here is to
raise the price of vaccines and reduce the likelihood of their dis-
semination. 114 And even when full attention is paid to the issue of
information transfer, the task of informing a widely disparate set of
persons is quite formidable because there is always the opportunity
for slippage in translation. Special conditions of individual plain-
tiffs could be overlooked; language and literacy barriers could easily
exist. Finally, a conscientious doctor or nurse could use a bit of
encouragement that would effectively negate the warning in full.
These are all issues that are better handled downstream than by a
manufacturing company that can ill-afford to monitor a process
that it cannot effectively control.
The key issue in many cases, however, arises when the desired
warning from the manufacturer is transferred to the recipient of
the drug or vaccine. Just what should that warning say? In line with
higher levels of judicial oversight, the hairsplitting begins over
whether they should be regarded as adequate for the occasion.
adults the risk to this group is greater; whereas, the risk to children is exceedingly
slight or practically nonexistent."). The duty to warn was also explicitly recog-
nized. Id. at 126.
111. See id. at 123.
112. See Reyes, 498 F.2d at 1270.
113. See id. at 1290.
114. For an estimate of the cost with respect to whooping cough vaccine, see
Peter Huber, Safety and the Second Best: The Hazards of Public Risk Management in the
Courts, 85 COLUM. L. REV. 277, 288 (1985) (noting that the whooping cough vac-
cine causes twenty-five cases of serious, long-term brain damage each year, while it
saves 413 lives). There is with these numbers no need for ex post compensation for
injuries. The huge reduction in total losses should supply compensation enough.
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Overly chill-inducing warnings that "paralytic disease following the
ingestion of live polio virus has been reported in individuals" can
be found inadequate because they do not say that this outcome is to
be expected. 115 There is a catch-22 here. It is wrong to make those
statements when the evidence does not support them. But let the
jury decide that the evidence cuts the other way, and it will then
deem these false statements as true, imposing liability on the
strength of its own misperceptions. In consequence, the vaccine
cases can usher in a destructive pattern of strategic behavior that
cannot be deployed against drug manufacturers when the down-
stream player is the only person who bears the risk of liability: A
plaintiff can settle with the doctor or other responsible intermedi-
ary and use his or her testimony to land the larger fish, the drug
manufacturer. This is precisely what happened in Wyeth v.
Levine.116
This trend extends beyond vaccines to other medical contexts.
Perhaps the most famous (or notorious) case of this sort is MacDon-
ald v. Ortho Pharmaceutical Corporation,117 which held that juries
could find a drug company liable under a duty-to-warn theory for
alleged injuries caused by birth control pills. 18 In MacDonald, un-
like in Davis and Reyes, no one doubted that the drug caused the
twenty-six year-old woman's stroke. The issue was whether the
warning could be adequate if it did not contain the word "stroke,"
even if it did warn that "[t] he most serious known side effect is ab-
normal blood clotting which can be fatal."1 19 The question of the
warning's adequacy was left to the jury as was the causation ques-
tion, or, more specifically, the question of how likely it would be
that someone who knew that a drug could be fatal would neverthe-
less decide to take the drug (to avoid some alternative peril) be-
cause she did not know that the fatal injuries could be caused by a
stroke. The marginal impact of the missing information has to be
judged against the background information already known. In this
case, it is not credible to think that this additional piece of informa-
tion could alter behavior. Yet even given the tiny omission in this
warning, causation in drug duty-to-warn cases will always be a jury
115. Givens v. Lederle, 556 F.2d 1341, 1343 (5th Cir. 1977); see also id. at 1345.
116. 129 S. Ct. 1187, 1191 (2009). The dangers of the odd dynamics of settle-
ment negotiations have been well known and are clearly set out injustice Stevens's
opinion in McDermott, Inc. v. AmClyde, 511 U.S. 202, 212-13 (1994) (noting how
under the credit rule the more responsible defendant can escape by paying less).
117. 475 N.E.2d 65 (Mass. 1985).
118. See id. at 71.
119. Id. at 66.
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question. The error costs of false positives are thus very high
indeed.
MacDonald also made clear that the drug company could not
escape liability because the plaintiff was in the care of a physician
who had all the relevant knowledge about her condition and the
drug in question.120 The downstream-only option was explicitly re-
jected in favor of a joint causation model that allowed the plaintiff
to simultaneously sue the drug company under a duty-to-warn the-
ory as well as the physician under a negligence theory by including
the physician's failure to meet the requirements of an informed
consent rule.12 1 Not surprisingly, by this time, the issue of federal
preemption did surface, because the FDA had approved the warn-
ing in question. That additional warning meant that any gap in
information had been addressed in the first instance by the FDA
warning. But far from letting that warning stabilize the overall situ-
ation, "the FDA commissioner specifically noted that the bounda-
ries of civil tort liability for failure to warn are controlled by
applicable State law." 122
IV.
WYETH V. LEV/NE, AT LAST
We are now in a position to put all the pieces together to see
how the great transformation in tort law creates a genuine tension
with the objectives of the food and drug laws. In duty-to-warn cases,
such as Wyeth, liability depends on the rejection of the full informa-
tion model; the unwillingness to accept technological specialization
at different stages of the production process; the adoption of exten-
sive theories ofjoint causation; the disregard of downstream abuse;
the ineffectiveness of disclaimers and contractual limitations; and
the use of collusive settlements between plaintiffs and downstream
actors. None of these elements was in play before the tort revolu-
tion of the late 1960s. In the modern environment, federal pre-
emption becomes the last line of defense against the combined
weight of all of these factors. The key point is that none of the
favorable state law doctrines could be invoked unless the plaintiff
could first claim that the FDA warning was inadequate. Yetjust that
possibility was blocked by the FDA preamble, which "interprets the
act to establish both a 'floor' and a 'ceiling"' in all duty-to-warn
120. See id. at 69.
121. See id. at 138-39, 139 n.13.
122. Id. at 70 (citing 43 Fed. Reg. 4214 (1978)).
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cases. 123 Once the FDA began treating its warning as setting both
maximums and minimums, it blocked liability at the outset; none of
the other changes in state product liability law mattered. Yet once
that barrier is overcome, the combined force of all the new state law
doctrines comes into play.
To understand how the state law doctrinal transformations
work in unison, start with Levine's complaint, alleging that the de-
fendant's warning was inadequate. In the words of Justice Stevens:
Although Phenergan's labeling warned of the danger of gan-
grene and amputation following inadvertent intra-arterial in-
jection, Levine alleged that it failed to instruct clinicians to use
the IV-drip method of intravenous administration instead of
the higher risk IV-push method. More broadly, she alleged
that Phenergan is not reasonably safe for intravenous adminis-
tration because the foreseeable risks of gangrene and loss of
limb are great in relation to the drug's therapeutic benefits.124
The choice of methods in this case depends on this cost-benefit
analysis.
The FDA concluded that a two-tiered strategy was correct. The
first-line treatment was the IV-drip method, which should be used
in most cases. But where the pain was acute and the system did not
work, resort to the second-line treatment might be appropriate on
the ground that the additional benefits might justify the riskier
method, at least if all appropriate precautions were taken. It should
be evident that each step in the use of the IV-push method relies on
optimal downstream actions, both in the evaluation of the risk and
the execution of the riskier IV-push procedure. The FDA, whose
warnings were tied to the sale and distribution of the drug, could
not make the individualized judgment. Downstream cooperation
was essential, and allowing for recovery in the face of the occa-
sional, if inevitable, downstream misuse by medical professionals
wrecked the coordination. There is no way for good doctors to get
sound information on product use if the warnings are designed to
prevent abuse by incompetent ones. Warning the doctor to take
extreme care makes perfectly good sense as a matter of overall sys-
tem design, and this is precisely what the Wyeth warning did when
it specified the quantity limitations on drug levels, the preferred
mode of application, the warning signs of danger, and the extreme
123. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 (2006).
124. Wyeth v. Levine, 129 S. Ct. 1187, 1192 (2009).
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level of care required. 1 2 5 I cannot think of anything that it should
have done differently.
But Levine sought to make an end-run around this system. In
a world of free jury discretion, the question of whether to use a pro-
cedure is always in play along with how to use the procedure. So
Levine's key tactic was to attack the risk-segmentation strategy by
insisting that Wyeth should have warned against any use of the IV-
push method. In her view, the bottom line was that Wyeth was neg-
ligent because it had not "earnestly attempted" to strengthen the
warning against any use of the IV-push method, and because the
evidence had shown that the risk of gangrene "can be almost en-
tirely eliminated through the use of the IV-drip." 126 Levine took
the same line in her interview, alluding to how the company might
have put profits before welfare in choosing not to issue that
warning:
Pharmalot: What's your view of Wyeth and its actions?
Levine: They should've taken responsibility for changing the
label . ... It's not a bad drug. It's a good drug, for what it is.
But I'd much rather throw up than lose my arm. I think they
should've come out and said that, under no circumstances
125. Id. at 1192 n.I. The warning for "Inadvertent Intra-arterial Injection"
stated:
Due to the close proximity of arteries and veins in the areas most commonly
used for intravenous injection, extreme care should be exercised to avoid per-
ivascular extravasation or inadvertent intra-arterial injection. Reports compat-
ible with inadvertent intra-arterial injection of Phenergan Injection, usually in
conjunction with other drugs intended for intravenous use, suggest that pain,
severe chemical irritation, severe spasm of distal vessels, and resultant gan-
grene requiring amputation are likely under such circumstances. Intravenous
injection was intended in all the cases reported but perivascular extravasation
or arterial placement of the needle is now suspect. There is no proven suc-
cessful management of this condition after it occurs.... Aspiration of dark
blood does not preclude intra-arterial needle placement, because blood is dis-
colored upon contact with Phenergan Injection. Use of syringes with rigid
plungers or of small bore needles might obscure typical arterial backflow if
this is relied upon alone. When used intravenously, Phenergan Injection
should be given in a concentration no greater than 25 mg per mL and at a
rate not to exceed 25 mg per minute. When administering any irritant drug
intravenously, it is usually preferable to inject it through the tubing of an in-
travenous infusion set that is known to be functioning satisfactorily. In the
event that a patient complains of pain during intended intravenous injection
of Phenergan Injection, the injection should be stopped immediately to pro-
vide for evaluation of possible arterial placement or perivascular
extravasation.
Id.
126. Id. at 1192.
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should the drug be administered under push IV. They didn't
protect me and ensure my safety .... They have strong eco-
nomic incentives and, sometimes, those things take prece-
dent .... They say the FDA is their first line of defense, but if a
drug company recognizes there's something that could hurt
the public, they have an obligation to do something. 127
Her belated demand for a stiffer warning or categorical exclu-
sion, however, ignores the benefit side of the cost-benefit equation.
In particular, it assesses the ex ante use of the IV-push method on
the strength of the ex post outcome in the one case that went awry.
The upstream side of the equation looks impenetrable for Wy-
eth. The last thing any jury should be allowed to do is to decide,
after the fact, that instructions on the use of the IV-push method
under any circumstances count as negligence per se. What is a
drug company supposed to do if one jury finds that Wyeth warnings
were accurate and thus denies liability, when a second jury regards
the failure not to insist on banning the IV-push method as negli-
gent? In the case where IV-push might have worked when the IV
drip failed, is it negligent not to have instructed on its use? Is it
possible to write and revise labels to give respect to two, or more,
inconsistent judgments?
It is also unclear what the FDA should have done in response
to the warning. Its chosen course of action was to insist that the
Black Box warning128 be used to highlight the risks of the TV-push
system.129 But there are real costs associated with the use of Black
Box warnings. They can over-deter patients from accepting treat-
ments whose benefits outweigh their costs. They also can deter phy-
sicians from using the Black Box treatment for fear of malpractice
127. Ed Silverman, Preemption and Amputation: Diana Fights Wyeth, Pharmalot.
com (Feb. 20, 2008), http://www.pharmalot.com/2008/02/preemption-and-am-
putation-diana-fights-wyeth/.
128. According to the Federal Register
Certain contraindications or serious warnings, particularly those that may lead
to death or serious injury, may be required by the FDA to be presented in a
box.... The box must contain, in uppercase letters, a heading inside the box
that includes the word "WARNING" and conveys the general focus of the in-
formation in the box. The box must briefly explain the risk and refer to more
detailed information in the "Contraindications" or "Warnings and Precau-
tions" section ....
21 C.F.R. § 201.57(c) (1) (2001).
129. See Press Release, U.S. Food and Drug Administration, FDA Requires
Boxed Warning for Promethazine Hydrochloride Injection (Sept. 16, 2009), avail-
able at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucml8
2498.htm.
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liability with the same effects. To require a Black Box warning in
response to the outcome of a single jury verdict in Vermont shows
how dubious jury verdicts can reorient national policy for the
worse.
The powerful influence of common law decisions creates gra-
tuitous expense and uncertainty that feed their way back into the
cycle of drug development, testing, and marketing. Properly un-
derstood, the entire duty-to-warn apparatus has become a tax on
drugs, which, in some instances, may drive both old and new prod-
ucts off the market and, in most instances, will increase drug cost
and reduce the levels of beneficial patient use. Yet any liability dis-
claimer for bad uses is dead in the water in the post-1965 period. 13 0
There is no set of warnings that could remove the risk of liability
after Wyeth and convey the message that TV-push has a net patient
benefit in some cases.
The outcome looks only worse when we look at downstream
behavior. Justice Alito's dissent notes that the plaintiff's suit was
originally against the physician, Dr. John Matthew, his assistantJes-
sica Fisch, and the local hospital. 31 Justice Alito also reports that
the two individual defendants settled with the plaintiff and testified
against Wyeth on her behalf, 32 but he does not comment on the
obvious risk of a collusive settlement.l 33 Justice Alito also noted
that two medical defendants offered profuse apologies for their
negligence, perhaps in order to increase their credibility before the
jury.134 Most instructively, he states that:
[H] er medical practitioners testified that they used IV-push in
order to help her "in a swift and timely way" when she showed
up at the hospital for the second time in one day complaining
of "intractable" migraines, "terrible pain," inability to "bear
light or sound," sleeplessness, hours-long spasms of "retching"
and "vomiting," and when "every possible" alternative treat-
ment had "failed."135
130. See RESTATEMENT (THi1RD) OF TORTS: PRODUCTS LIABILITY § 18 (1997)
("Disclaimers and limitations of remedies by product sellers or other distributors,
or waivers by product purchasers, and other similar contractual exculpations, oral
or written, do not bar or reduce otherwise valid products liability claims against
sellers or other distributors of new products for harm to persons.").
131. Wyeth, 129 S. Ct. at 1218 n.3 (Alito, J., dissenting).
132. Id.
133. Cf Booth v. Mary Carter Paint Co., 202 So. 2d 8, 8 (Fla. Dist. Ct. App.
1967). For critical commentary, see Lisa Bernstein & Daniel Klerman, An Economic
Analysis of Mary Carter Settlement Agreements, 83 GEo. L.J. 2215 (1995).
134. Wyeth, 129 S. Ct. at 1218 (AlitoJ., dissenting).
135. Id. at 1226 (Alito, J., dissenting).
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That version of the facts jibes perfectly with Levine's. In an
interview about her case, she gave the following account:
Pharmalot: But in 2000, you went to the hospital and Phener-
gan was administered. What happened?
Levine: I have a history of these migraines and, normally, I can
manage them, but on occasion, they could be excruciating and
debilitating, and I'd get hauled off to the emergency room.
Normally, I'd get Demerol for the pain and then Phenergan,
because the Demerol would make me nauseous. And it would
be intramuscular administration, which was normally a shot in
the butt. This time, they gave me a push IV and that's what
caused the problem. When I woke up, I was still in pain.13 6
Which way does her testimony cut? The evidence shows that
Levine's case was serious, one for which neither the FDA nor Wyeth
should rule the IV-push method out of bounds. It proves that the
physician and his assistant knew which cases needed only the first-
line approach and which cases called for the second-line approach,
which, if properly executed, might have provided much needed pal-
liation. This account of the facts makes it clear that Dr. Matthew
and Ms. Fisch were not negligent in ordering the IV-push given
their prior failure with the less aggressive technique. Justice Ste-
vens, however, studiously declined to mention what their negligent
actions and omissions were. He notes twice that the warnings speci-
fied that Phenergan "should be given in a concentration no greater
than 25 mg/ml and at a rate not to exceed 25 mg/minute."137 But
he did not say that it was the admitted failure to follow those precise
instructions that prompted their profuse apologies.
And Levine did no better when she recounted the case. She
mentioned that she got the IV-push but did not utter a word about
the misconduct of Matthew and Fisch. That information was, of
course, included in Wyeth's brief, which reads as follows:
Although Phenergan's labeling specified a dosage range for
nausea of 12.5 to 25 mg, Fisch gave respondent a 50 mg dose-
double the labeled amount. Moreover, Fisch administered the
entire 50 mg double dose without pausing, despite respon-
dent's complaints of pain-pain she later described as "one of
the most intense pains that [she] had ever felt" to that point-
136. Silverman, supra note 127.
137. 129 S. Ct. at 1192 n.1.
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even though the labeling instructed that IV injection should
stop immediately if the patient complains of pain. 138
It is also worth noting that an injection into an artery produces
a wholly different response than an injection into a vein. Arterial
pressure is roughly 100 mm (of mercury) 139 while that of venal
pressure is usually, approximately a tenth that amount. 140 An arte-
rial injection typically produces spurting of blood, which sometimes
is strong enough to dislodge a needle. Neither of these happens
with an intravenous injection. Here, the responsibility to monitor
the downstream risk of arterial injection lay exclusively with Ms.
Fisch. If there is a claim for negligent supervision, it lies against Dr.
Mathews. Wyeth should be nowhere in the mix. At bottom, the
only risks that came to pass in obvious fashion at the downstream
level were the ones that the Wyeth warnings and instructions had
specifically taken into account. To put it mildly, the deviation from
the stated warnings "increased the risk or hazard" of the injury suf-
fered far beyond what would have happened if the correct proce-
dures had been followed. And the use of a theory ofjoint causation
in these circumstances can only be described as a grotesque exten-
sion of sound tort theory, which is not made any more palatable by
its constant use.
It is unassailable as a matter of law that successive actions of
negligence render both defendants responsible. 141 That is true
where one defendant digs a hole that the other does not see before
he falls in. But it should not hold where the first person has filled a
hole into which the second decides to jump head first. Unfortu-
nately, once the full information model is rejected, the theory of
joint causation gobbles up all sorts of defendants who should be
categorically insulated from liability.
These massive doctrinal errors are now compounded by settle-
ments that build off the underlying tort doctrine. Settlements gen-
erate little complexity in two-party situations. But strategic
settlements between two parties are capable of creating real nega-
tive externalities against any third person not party to the agree-
ment. Whether the third person will be hurt depends critically on
138. Brief of Petitioner Wyeth at 20, Wyeth v. Levine, 129 S. Ct. 1187 (2009)
(No. 06-1249) (citations omitted).
139. See RODNEY RHOADES & RIHARD PFLANZER, HUMAN PHYSIOLOGY 590-91
(4th ed. 2003).
140. See id. at 606-07 ("The pressure in the venules and small veins is only
about 10 mm Hg.").
141. See, e.g., Atherton v. Devine, 602 P.2d 634, 636 (Okla. 1979) (original
wrongdoer not excused by negligence of treating physician).
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how the initial settlement between the plaintiff and the first defen-
dant(s) affects the potential liability of the remaining nonsettling
defendant. Everyone agrees that once a given defendant has settled
with the plaintiff he is protected from a cross-claim by a nonsettling
defendant. Without that protection, no settlements will take place.
But the question remains: What effect does the first settlement have
on the subsequent litigation of the claims against the nonsettling
defendants?
One rule, called the "proportionate share" or "carve-out" rule,
holds that the plaintiff who settles with one defendant loses the en-
tire portion of the loss attributable to that claimant. Under this
rule, if the physician and assistant's apportionment of liability is
ninety percent, then ninety percent of the claim is gone whether
they settle for a lot or a little. The plaintiff knows she can only
recover ten percent of the total loss against the remaining defen-
dant. This rule is used in admiralty in order to avoid strategic set-
tlements, as ably explained in Justice Stevens's earlier opinion in
McDermott, Inc. v. AmCLYDE. 142
But Vermont does not follow the carve-out rule. 143 Instead, it
follows the pro tanto rule, which gives the second defendant a credit
against final judgment equal to the amount paid out by the settling
defendant. Under this rule, the risks of strategic bargaining are
manifest, for it is widely understood that the bulk of responsibility
for compensation could be placed on the wrong defendant, which
is why Justice Stevens wisely opted for the proportionate share rule
in admiralty cases. 144
To make the difference explicit, suppose that we decide (chari-
tably for Matthew and Fisch) that these defendants were ninety per-
cent responsible for the $7,400,000 settlement. If they settled for,
say, $500,000 under the Vermont rule, Wyeth is left with $6,900,000
in damages. But if the proportionate share disappears, the oppor-
tunity for game-playing by early settlement vanishes, and the plain-
tiff can get only $740,000 from Wyeth regardless of the order in
which the suits against the separate defendants resolved. The
credit rule thus leaves Wyeth at the mercy of the downstream play-
ers. When the dust settles, Wyeth gets slapped with the bulk of the
damages, every bit of which should be paid by downstream actors.
142. 511 U.S. 202, 215-16 (1994).
143. See Wyeth, 129 S. Ct. at 1193 (noting Vermont's use of the credit rule).
144. For an explanation, see McDermott, 511 U.S. at 217; Am. Motorcycle Ass'n
v. Super. Ct., 578 P.2d 899, 919-20 (Cal. 1978) (Clark, J. dissenting).
Imaged with the Permission of NYU Annual Survey of American Law
2010]
518 NYU ANNUAL SURVEY OF AMERICAN LAW [Vol. 65:485
V.
BEYOND WYETH
There is little doubt that Wyeth poses major obstacles for pre-
emption defenses in duty-to-warn cases brought against drug manu-
facturers. On its facts, Wyeth is an uncommon case because of the
infrequency with which downstream physicians and physician assist-
ants will be as grossly negligent as Dr. Mathews and Ms. Fisch. But
the same rules on field and conflict preemption also apply to the
many cases in which drugs are alleged to cause harm wholly without
regard to the palpable negligence of those who administer them.
The litmus test is as follows: A detailed warning will preempt only if
the FDA precisely addresses potential risks in a manner that
Sharkey and Rabin support.1 45
This issue is raised by cases involving suicides committed by
depressed persons, previously medicated by selective serotonin
reuptake inhibitors, or SSRIs. For example, in Colacicco v. Apotex
Inc., 146 the decedent Lois Colacicco, age fifty-five, had been put on
Paxil, a generic SSRI, and committed suicide less than one month
later. At the time of her death, the Paxil labeling included a spe-
cific warning about the possibility of suicide attempts. 14 7 In a com-
panion case, a patient was prescribed Zoloft for anxiety and
depression, and committed suicide a week later. The label for
Zoloft also explicitly warned of suicide. 148
In Colacicco, Judge Sloviter offered an extensive demonstration
of FDA oversight that relied on its Psychopharmacological Drugs
Advisory Committee. The Committee rejected the need for addi-
tional warnings on SSRIs, and in 1991, 1992, and 1997, the agency
had rejected citizen petitions to either take Prozac (an SSRI) off the
market or require additional warnings. 149 Judge Sloviter was cor-
145. See Rabin, supra note 30; Sharkey, supra note 30.
146. 521 F.3d 253 (3d Cir. 2008).
147. See id. at 256 (noting that the "Precautions" section of the label included
the following language: "Suicide: The possibility of a suicide attempt is inherent in
major depressive disorder and may persist until significant remission occurs. Close
supervision of high-risk patients should accompany initial drug therapy. Prescrip-
tions for PAXIL should be written for the smallest quantity of tablets consistent
with good patient management, in order to reduce the risk of overdose ...").
148. See id. at 257 (noting that the precautionary language for Zoloft included
the following: "Suicide-The possibility of a suicide attempt is inherent in depres-
sion and may persist until significant remission occurs. Close supervision of high
risk patients should accompany initial drug therapy. Prescriptions for Zoloft (ser-
traline) should be written for the smallest quantity of capsules consistent with good
patient management, in order to reduce the risk of overdose.").
149. See Colacicco, 521 F.3d at 269.
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rect to conclude that "[t]he FDA has actively monitored the possi-
ble association between SSRIs and suicide for nearly twenty years,
and has concluded that the suicide warnings desired by plaintiffs
are without scientific basis and would therefore be false and mis-
leading."150 This makes sense. Virtually everyone who takes an
SSRI is drawn from a suicide-prone portion of the population. No
doubt some people on these drugs will commit suicide, but there is
always an argument as to whether that desperate act was a function
of the prior condition alone, the drug alone, or some combination
of the above. Any effort to sort out that form of causation in an
individual case is bound to fail.
It is, however, no surprise that the vast majority of deaths that
occur after one goes on SSRIs results in lawsuits. This will continue
to happen unless the preemption defense is rock solid. It is impos-
sible to decide in a single case whether a person who commits sui-
cide after a week or a month, as in these cases, did so because the
drug had not yet had time to work, was not going to work at all, or
pushed someone over the edge. That causation question is fair
game in all cases, and is, under current law, the type of issue on
which summary judgment against the plaintiff will not be granted,
no matter the statistics on the rate of suicides for those who do and
do not take an SSRI.15'
What matters is not the etiology of the individual case but
rather the overall distribution of suicides. We know from the re-
cent aggregate data that the decision to place the Black Box warn-
ing on Prozac reduced its use for the reasons stated above1 52 and
may have also caused some increase in suicides in young popula-
tions. 153 The usual-and correct-caution about the interpreta-
tion of data means that the correlations could well turn out to be
150. Id.
151. See supra text accompanying notes 120-21 (noting that causation is a
question for the jury).
152. See supra text accompanying notes 128128-29.
153. See Robert D. Gibbons et al., The Relationship Between Antidepressant Pre-
scription Rates and Rate of Early Adolescent Suicide, 163 AM. J. PSYCHIATRY 1898 (Nov.
2006), which reports as follows:
RESULTS: After adjustment for sex, race, income, access to mental health
care, and county-to-county variability in suicide rates, higher SSRI prescription
rates were associated with lower suicide rates in children and adolescents.
CONCLUSIONS: The aggregate nature of these observational data precludes
a direct causal interpretation of the results. More SSRI prescriptions are asso-
ciated with lower suicide rates in children and may reflect antidepressant effi-
cacy, treatment compliance, better quality mental health care, and low toxicity
in the event of a suicide attempt by overdose.
Id. at 1898.
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positive at which point we can fully expect psychiatrists to take the
necessary corrective action in the interests of their patients.
What becomes clear is that no legal regime is truly sustainable
if matters as complex as this are trusted to juries to make of the
evidence what they please. It is critical in this context to remember
that each and every jury trial in these suicide cases has to conclude
both that the drug caused, alone or in combination, the suicide and
that the existence of a stronger warning would have made a differ-
ence, given that the warning in question is strong already. If a jury
is seventy percent confident on each issue, the likelihood that the
plaintiff has made out all elements of his or her case is still below
fifty percent. Most cases of this sort will not come close to meeting
the standard of a preponderance of the evidence for the entire
case. The upshot is that the huge expense of defending these cases
will lead to a shrinkage in the use of SSRIs, which, if appropriate,
should be taken for medical reasons, not for a fear of liability gone
amok.
The entire jury process represents yet another instance of how
it is possible to spend a fortune in litigation only to achieve an infer-
ior outcome to that which could be reached by using a field pre-
emption theory to block all these suits in their inception. But that
result, as Judge Sloviter notes, cannot be "seriously" pursued to-
day. 154 Given that juridical reality, she conducts no independent
analysis as to the soundness of her rules. Nor, it appears, will the
Supreme Court, which summarily returned the case to the Third
Circuit.1 55 Originally, the two district courts split on the preemp-
tion question, and it is of course possible that the same result will
arise on remand. 156 But as to the warnings, there is little that distin-
guishes Prozac from Phenergan except the mechanism of causa-
tion, which is far more complicated for the former drug than for
the latter. So on balance, even I would be forced, against my better
judgment, to refuse to find preemption in Colacicco after Wyeth; the
doctrine is all but dead in these cases.
VI.
CONCLUSION: PREEMPTION AT LAST
Linking up all these disparate pieces reveals two essential pro-
positions. The first goes to the historical arc of the tort law and its
154. Colacicco, 521 F.3d at 262.
155. See Colacicco v. Apotex Inc., 129 S. Ct. 1578, 1578-79 (2009) (remand-
ing for further consideration in light of Wyeth).
156. See Colacicco, 521 F.3d at 256-57.
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relationship to federal preemption. It is simply incorrect to think
that the relatively limited and sensible doctrines of the pre-1965 pe-
riod gave rise to any occasion requiring the preemption issues seen
today. Tension arose only after two prominent developments in
product liability laws. First, courts' refusal to honor contractual lim-
itations on liability opened up the possibility of tort liability, gener-
ating excessive deterrence-if parties had contracted as to the ideal
risk allocation, ignoring such agreements constituted a deviation
from optimal deterrence. Second was the decision, as a matter of
state law, to treat FDA warnings as adequate with respect to drug
risks. At this point, where tort liability is generally available but a
federal agency has sent a different message by approving warnings,
all the pressure falls on the doctrine of implied preemption. Un-
fortunately, Justice Stevens's profound misunderstanding of the his-
torical evolution of tort law prompted him to adopt the
mischievous substantive position articulated by Kessler and Vladeck,
which wrongly assumes that the only failures of the FDA are to let
too many new drugs onto the market with warnings too weak for
the occasion, with no failures in the opposite direction. 157 If there
was ever a reason to apply the doctrine of "changed circumstances"
in understanding the relationship between litigation and the ad-
ministrative state, this was it. Why federal preemption should ig-
nore that profound sea change for the worse is never explained.
For whatever it is worth, Riegel presents the same pattern of
downstream disregard of explicit warnings and instructions that Wy-
eth did. The defendant physician used the defendant's angioplasty
device at pressures higher than those for which it was rated. 15 It
could well have been that the treating physicians made a correct
downstream judgment that exceptional circumstances called for ex-
ceptional treatment in disregard of the explicit warnings and in-
structions. Such a deviation from standard practice is, of course,
not negligence per se, given just this possibility.159 Right now, legis-
lation is before Congress to remove the explicit bar to preemption
in medical device cases, 160 so that Riegel could go the same way as
Wyeth, even though the reverse result is sorely needed. But the use
157. See Wyeth v. Levine, 129 S. Ct. 1187, 1203 n.12 (2009) (citing Kessler &
Vladeck, supra note 26).
158. See Riegel v. Medtronic, Inc., 552 U.S. 312, 320 (2008).
159. See RESTATEMENT (SECOND) OF TORTS § 288A (1965); RESTATEMENT
(THIRD) OF TORTS: LIABILITY FOR P-rvsicAL HARM § 12 (Proposed Final Draft No. 1,
2005).
160. See Medical Device Safety Act of 2009, S. 540, H.R. 1346, 111th Cong. § 2
(2009) (amending Section 521 of the Federal Food, Drug, and Cosmetic Act, 21
U.S.C. § 360K, by adding the following language: "Nothing in this section shall be
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of tort law in modem circumstances makes it harder to be sure that
safe and effective drugs can be delivered to the public at large.
The judicial failure to understand the historical arc of the law
of torts leads to a second set of unsound judgments on matters of
institutional competence-the second proposition. There is noth-
ing that erratic and expensive juries can do to make accurate scien-
tific judgments that will allow people to plan their conduct in
advance. Stability of expectations is indispensable in marketing
dangerous compounds, and, for all its manifest failings, the FDA is
better at this task than juries. So even if one utterly rejects market
solutions to drug liability, there is still no reason to embrace the
looming no-preemption regime in drug cases.
Congress's stated purpose in establishing the FDA, as taken
from the 1962 amendments to the FDCA, was to "assure the safety,
effectiveness, and reliability of drugs, authorize standardization of
drug names, and clarify and strengthen existing inspection author-
ity . "..."161 How, institutionally, does this square with a system that
allows juries to override systematic decisions by a risk-averse agency
without having to say a word on their behalf? If the state of Ver-
mont wanted to impose a $1,000 fine on Wyeth for using its Phener-
gan label, its action would surely be preempted. But a $6 million
tortjudgment that offers none of the procedural protections of the
administrative state is said to pose no threat to the integrity of the
federal system.
In sum, the imposition of past liability and the threat of future
liability pose a serious threat to the continued viability of what Di-
ana Levine called a "good" drug. Yet Justice Stevens appears to be
oblivious to the institutional chaos that his decisions introduce.
Thus in Bates v. Dow Agrosciences, LLC,162 he held against preemp-
tion, stating:
A requirement is a rule of law that must be obeyed; an event,
such as a jury verdict, that merely motivates an optional deci-
sion is not a requirement. The proper inquiry calls for an ex-
amination of the elements of the common-law duty at issue...
it does not call for speculation as to whether a jury verdict will
prompt the manufacturer to take any particular action. 163
construed to modify or otherwise affect any action for damages or the liability of
any person under the law of any State.").
161. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962)
(codified as amended in various sections of 21 U.S.C.).
162. 544 U.S. 431 (2005).
163. Id. at 445.
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His naively optimistic account assumes that all that can be expected
in response to a major liability shock is a label change. But as the
Bendectin saga of the 1980s shows, sometimes warning changes will
not do the work, and drugs are pulled from the market. 164 That is
not likely to happen with Phenergan because staggering incompe-
tence inside the hospital is not likely to be a common occurrence.
The makers of Bendectin did not have that protection because the
birth defects were said-incorrectly-to arise from the prescribed
usages of the product. 165 Yet the massive disruption that even a
single trial causes to a blameless product makes the pro-preemption
conclusion entirely appropriate. Unless and until someone writes a
warning that can provide conscientious drug makers with a safe har-
bor, the entire system will have less to do with warning patients than
with second-guessing drug warnings in courts.
Justice Stevens's decision to belittle conflict preemption in Wy-
eth, after the passage of the FDAAA, is indefensible. 166 There was
no new information that indicated that the older understandings
were defective. To the contrary, Wyeth reveals facts that show how
unwise it is to adopt a per se rule against IV-push. This entire epi-
sode reaffirms the wisdom of the pre-1965 products liability tort
law, which, if adopted, would allow the confused doctrine of federal
preemption to fade into the woodwork. But this is a second-best
world, in which state law has to be taken as a given, warts and all.
Any federal preemption must be evaluated against the tort law as it
is, not as it was once or should be. By that standard, Wyeth was
decided wrongly-egregiously so.
164. For an account of the demise of Bendectin, see Lynch v. Merrell-National
Labs., Inc., 830 F.2d 1190, 1194 (1st Cir. 1987) (noting a decline in usage from one
million new therapy starts in 1979 to zero in 1984).
165. See id. (noting no change in the incidence of birth defects following the
removal of Bendectin from the market).
166. See Wyeth v. Levine, 129 S. Ct. 1187, 1195-96 (2009).
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